Clostridium Difficile Clinical Trial
Official title:
Prevention of Clostridium Difficile Infections Using Lactobacillus Plantarum 299v Strain in Nephrology and Transplantation Department
The aim of this study was to analyze whether the use of the LP299v strain reduces the risk of
Clostridium difficile infection (CDI) among patients receiving antibiotics and hospitalized
in the nephrology and transplantation ward.
Patients from risk group (receiving immunosuppressive drugs and treated with antibiotics)
were enrolled into study.
Participants will be divided into two groups. First group will receive one capsule of
Lactobacillus plantarum 299v (LP299v) orally per a day. Second group will receive placebo.
Clostridium difficile is currently the most frequently identified pathogen causing
antibiotic-associated diarrhoea and the main cause of nosocomial diarrhoea. In regard to
observed worldwide increase rate of infection and mortality from CDI the prevention of
Clostridium difficile infections seems to be crucial, especially in patients at CDI high
risk. So far, it has not been unambiguously proven that probiotics are effective in the
prevention of Clostridium difficile infection among patients undergoing antibiotic therapy.
The Lactobacillus plantarum 299v (LP299v) is a Gram-positive lactic acid bacteria that
naturally occurs on the surface of human intestinal mucosa. Specific properties to the gut
mucosa colonization are due to mannose-dependent adhesion of LP299v to the epithelium of
human intestines.This ability of LP299v leads to reduction of bacterial translocation from
the intestinal lumen into the blood vessels, can prevent adhesion of many pathogens to
intestinal epithelium and modulate the inflammatory response of the epithelium. The strain
299v of Lactobacillus plantarum has been found to decrease the severity of gastrointestinal
adverse effects during antibiotic therapy. Limited data are available regarding the efficacy
of LP299v for preventing Clostridium difficile infections.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02896244 -
AssessmeNT of the Incidence of Clostridium Difficile Infections in Hospitalized Patients on Antibiotic TrEatment
|
||
| Recruiting |
NCT06071312 -
FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach
|
Phase 1/Phase 2 | |
| Recruiting |
NCT01973465 -
Fecal Microbiota Therapy for Recurrent Clostridium Difficile Colitis
|
N/A | |
| Terminated |
NCT01048567 -
Efficacy and Safety of Lactobacillus Acidophilus/Rhamnosus Combination for the Prevention of Antibiotic-associated Diarrhea in the Elderly
|
Phase 2 | |
| Completed |
NCT01066221 -
Comparative Study of Three Different Testing Mechanisms for Clostridium Difficile
|
N/A | |
| Not yet recruiting |
NCT03586206 -
Relationship Between C. Difficile Toxins' Serum Level With C. Difficile Infection
|
||
| Completed |
NCT02563106 -
A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI
|
Phase 2 | |
| Completed |
NCT02857582 -
Transplantation of Cultured Gut Microflora to Repeat Antibiotic-induced Diarrhea Due to Clostridium Difficile
|
Phase 2 | |
| Completed |
NCT02207140 -
Effect of Multi-species Probiotic HOWARU® Restore, on Gut Microbiota of Elderly
|
Phase 0 | |
| Not yet recruiting |
NCT01942447 -
Fecal Microbiota Transplantation in Recurrent or Refractory Clostridium Difficile Colitis
|
N/A | |
| Active, not recruiting |
NCT01703494 -
Fecal Transplant for Relapsing C. Difficile Infection
|
Phase 2 | |
| Completed |
NCT01813500 -
Host Immune Response to Clostridium Difficile Infection in Inflammatory Bowel Disease Patients
|
N/A | |
| Completed |
NCT01087892 -
Probiotics in Preventing Antibiotic Associated Diarrhoea Including Clostridium Difficile Infection
|
N/A | |
| Suspended |
NCT00591357 -
Efficacy of Loperamide for C. Difficile Colitis and Other Diarrheal Diseases Associated With Antibiotic Therapy
|
Phase 4 | |
| Recruiting |
NCT00377078 -
Use of Recombinant Human Lactoferrin in Long-Term Care Patients With Feeding Tubes With Clostridium Difficile.
|
N/A | |
| Completed |
NCT02254967 -
A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population
|
Phase 4 | |
| Terminated |
NCT01775397 -
A Post-marketing, Blinded Study to Investigate How Effective Fidaxomicin is Compared to Vancomycin in the Sustained Cure of Clostridium Difficile Infection in Adults That Are Receiving Therapy to Suppress the Immune System
|
Phase 4 | |
| Terminated |
NCT03617172 -
PROCLAIM -- Misoprostol in the Prevention of Recurrent CDI Prevent Recurrence of Clostridium Difficile Infection With Misoprostol
|
Phase 2 | |
| Recruiting |
NCT05622721 -
REMBRANDT: REcovery of the MicroBiome fRom Antibiotics for Dental implanTs
|
||
| Completed |
NCT02437487 -
SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI)
|
Phase 2 |